Specialist dermatology and oncology company Incanthera [AQSE:INC.PL] has signed a breakthrough deal with Marionnaud in Switzerland and Austria for distribution of its proprietary Skin + CELL high end skincare range.
Marionnaud is part of the A.S. Watson Group, one of the largest international health, beauty and lifestyle brand retailers globally.
Aquis-listed Incanthera said it is seeing some very positive market forecasts on the sale of Skin + CELL by Marionnaud. The deal is expected to generate significant revenues for the skincare company next year and beyond.
Incanthera said that Skin + CELL will be available exclusively through the Marionnaud stores in the Swiss and Austrian markets from Q2 2024, with a projected roll out across 1100 stores in other European markets after that. Further roll outs are also being planned for the highly lucrative luxury skincare market in Asia. This will leverage the massive retail penetration of the A.S. Watson Group.
Incanthera said it was manufacturing 25,000 units of Skin + CELL to meet the launch in central Europe next year. Manufacturing of the skincare range is being sub-contracted out to Frike in Switzerland, which has a 70 year track record of making luxury skincare products.
“I love the new Skin + CELL skin creams based on Incanthera’s unique skincare technology,” said Daniel Mertl, a product manager with Frike Cosmetic in Switzerland. “I see a lot of skincare products come and go in my role as global product manager for sales at Frike and Skin + CELL is definitely one of the most exciting products I have seen in a very long time. I really believe in its future success, and I am very happy Frike can be part of this.”
Incanthera’s skincare technology harnesses unique delivery pathways through recently patented formulations designed by the company’s in-house experts who have previously formulated skincare for some of the world’s leading skincare and pharmaceutical companies.
These formulations fortify otherwise depleted physiological pathways to improve the skin’s performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.
Skin + CELL’s formulations are enriched with targeted bioactive B3 (an activated form of niacinamide) which is delivered directly into the skin’s cells to optimise cellular health, energy and protective capabilities. Independent studies show Incanthera’s technology is uniquely effective in delivering Bioactive B3 below the dermal barrier, energising the living cells of the skin to maintain natural health and protection against adverse environmental challenges and maintaining even skin tones.
Incanthera sees over-subscribed fund raise
In order to fund the initial launch orders and to provide it with additional working capital, Incanthera has raised £1 million by way of a subscription and conversion for new ordinary shares at a premium.
The fundraise, which was oversubscribed and supported by both new institutional investors and existing long term institutional shareholders, has raised £800,000 by way of a subscription for 11,428,571 new ordinary shares at a price of 7p per Subscription Share, an 11.1% premium to the mid-price at close of trading on Friday, 15 December 2023 of 6.30p.
Incanthera said it is optimistic that manufacturing for future orders will be funded by way of trade finance, preserving equity value for shareholders.
